This is a preview of subscription content, log in via an institution to check access.
References
Rosati RL, Jardine PDS, Cameron KO, et al. Discovery and sar of a potent non-steroidal estrogen agonist, CP-336,156 [abstract no. 212]. 212th American Chemical Society National Meeting; 1996 Aug 25–29; Orlando, 205
Pfizer cancer treatment portfolio has four candidates nearing clinic. FDC Reports — Pink Sheet — Prescription Pharmaceuticals and Biotechnology 1998 Nov 16; 60: 19
Ke HZ, Oi H, Crawford DT, et al. A new selective estrogen receptor modulator, CP-336,156, preserves bone mass and bone strength, decreases total serum cholesterol without causing prostate hypertrophy in a model of male osteoporosis. Bone 1998; 23 (5 Suppl.): 183
Rosati RL, Da Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998 Jul 30; 41: 2928–31
Rights and permissions
About this article
Cite this article
CP 336156. Drugs R&D 1, 213–214 (1999). https://doi.org/10.2165/00126839-199901030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901030-00004